Michael Hofman

Michael Hofman

Company: Peter MacCallum Cancer Centre

Job title: Director - Prostate Cancer Theranostics & Imaging Centre of Excellence


Utilizing Diagnostics to Inform Patient Stratification and Selection in Clinical Trials 11:30 am

Molecular imaging with PET/CT provides immense value for both patient selection and as a prognostic/predictive biomarker For PSMA theranostics, the value of FDG in addition to PSMA PET/CT will be highlighted It is particularly critical for phase I/II to enrich patients likely to benefit from therapyRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.